FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Genomma Lab InternacionalB de CV FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Genomma Lab InternacionalB de CV FCF Yield % Related Terms
Genomma Lab InternacionalB de CV FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV FCF Yield % Chart
MEX:LABB vs ZTS, UTHR, VTRS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a FCF Yield % of 13.19 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 65% above median its historical median of 7.99. Over the past decade, Genomma Lab InternacionalB de CV's FCF Yield % has ranged from 2.33 to 19.29. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #85 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 8.5%.
Is Genomma Lab InternacionalB de CV's FCF Yield % too high?
Genomma Lab InternacionalB de CV's current FCF Yield % of 13.19 is 65% above median its 10-year median of 7.99. Over the past 10 years, this metric has ranged from a low of 2.33 to a high of 19.29. The Drug Manufacturers industry median FCF Yield % is 0.67. Genomma Lab InternacionalB de CV's value of 13.19 is 1868.7% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #85 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #85 out of 1005 companies for FCF Yield %. This places Genomma Lab InternacionalB de CV in the top 9% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Genomma Lab InternacionalB de CV's value of 13.19 is 1868.7% above this benchmark. Historically, Genomma Lab InternacionalB de CV's own FCF Yield % has ranged from 2.33 to 19.29 over the past decade. While the company's 10-year median is 7.99 vs. the industry median of 0.67, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current FCF Yield % of 13.19 is 1868.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current FCF Yield % is 13.19, which is 65% above median its own 10-year median of 7.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current FCF Yield % is 13.19, which is 65% above median its 10-year median of 7.99 and 1868.7% above the Drug Manufacturers industry median of 0.67. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current FCF Yield % is 13.19 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
FCF Yield %: 13.19 (65% above median its 10-year median of 7.99)
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
Industry Position: 1868.7% above the Drug Manufacturers median (#85 of 1005)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
